| sIPTH | serum immunoreactive parathyroid hormone |
|---|---|
| ER | efficiency ratio; epigastric region; ejection rate; electroresection; emergency room; endoplasmic re... |
| RAR | rapidly adapting receptor; rat insulin receptor; retinoic acid receptor; right arm reclining; right ... |
| GHRHR | growth hormone-releasing hormone receptor |
| LHRHR | luteinizing hormone-releasing hormone receptor |
| receptor aggregation | Chemically stimulated aggregation of cell surface receptors, which potentiates the action of the effector cell. (12 Dec 1998) |
|---|---|
| receptor agonist | A substance that mimics a specificneurotransmitter, is able to attach to that neurotransmitter's receptor and thereby produces the same action that theneurotransmitter usually produces. Drugs are often designed as receptor agonists to treat a variety of diseases and disorders whenthe original chemical substance is missing or depleted. (22 May 1997) |
| receptor-CD3 complex, antigen, T-cell | Molecule composed of the non-covalent association of the T-cell antigen receptor (receptors, antigen, T-cell) with the CD3 complex (antigens, CD3). This association is required for the surface expression and function of both components. The molecule consists of up to seven chains: either the alpha/beta or gamma/delta chains of the T-cell receptor, and four or five chains in the CD3 complex. (12 Dec 1998) |
| receptor, chemokine | A molecule that receives a chemokine and acts as a dock for a chemokine. Several chemokine receptors are essential co-receptors for HIV. (12 Dec 1998) |
| receptor downregulation | A phenomenon observed in many cells: following stimulation with a ligand the number of receptors for that ligand on the cell surface diminishes because internalisation exceeds replenishment. Often used very loosely, thus destroying the utility of the term. (18 Nov 1997) |
| receptor mediated endocytosis | Endocytosis of molecules by means of a specific receptor protein that normally resides in a coated pit, but may enter this structure after complex formation occurs. The structure then forms a coated vesicle that delivers its contents to the endosome whence it may enter the cytoplasm or the lysosomal compartment. Many bacterial toxins and viruses enter cells by this route. (18 Nov 1997) |
| receptor potential | The transmembrane potential difference of a sensory cell. Such cells are not generally excitable, but their response to stimulation is a gradual change in their resting potential. (18 Nov 1997) |
| receptor protein | An intracellular protein (or protein fraction) that has a high specific affinity for binding a known stimulus to cellular activity, such as a steroid hormone or adenosine 3',5'-cyclic phosphate. (05 Mar 2000) |
| receptor protein-tyrosine kinase | <enzyme> A catalytic protein-tyrosine kinase domain found on the cytoplasmic beta-portion of receptors. Many growth and differentiation factor receptors contain this domain. It is critical for the signal transduction pathways required for mitogenesis, transformation, and cell differentiation. Registry number: EC 2.7.1.- (12 Dec 1998) |
| receptor site | Point of attachment of viruses, hormones, or other activators to cell membranes. (05 Mar 2000) |
| receptor tyrosine kinase | Class of membrane receptors that phosphorylate tyrosine residues. Many play significant roles in development or cell division. Examples: insulin receptor family, c ros receptor, Drosophila sevenless, trk family. (18 Nov 1997) |
| receptor, visual | The layer of rods and cones, the visual cells, of the retina. (12 Dec 1998) |
| Cek4 receptor protein-tyrosine kinase | <enzyme> Isolated from mouse and chicken. Registry number: EC 2.7.1.- Synonym: cek4 protein, cek4 eph receptor, eph receptor cek4 (26 Jun 1999) |
| visual receptor cells | The rod and cone cell's of the retina. (05 Mar 2000) |
| glutamate receptor | <physiology> See amino acid receptor superfamily. Glutamate receptors are implicated in many important brain functions including long-term potentiation (LTP). at least 4 major glutamate gated ion channel subtypes are presently distinguished on pharmacological grounds, named after their most selective agonists: N methyl D aspartate (NMDA implicated in memory and learning, neuronal cell death, ischaemia and epilepsy), kainic acid (KA), quisqualate/AMPA and L 2 amino 4 phosphobutyrate (APB). A fifth subtype (APCD) trans 1 amino cyclopentane 1,3 dicarboxylate is a G-protein coupled receptor. (18 Nov 1997) |